News Daily News Remission From Prediabetes Halves CV Risk: Registry Data Yael L. Maxwell December 19, 2025
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News AI-Supported Coaching Shows Promise for Improving Glycemic Control L.A. McKeown August 25, 2025
News Daily News Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC Yael L. Maxwell August 18, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024